Iker Huerga/LinkedIn
May 17, 2025, 10:22
Iker Huerga: Pathos AI Secures $365M in Series D financing to Transform Oncology Drug Development
Iker Huerga, CEO at Pathos AI, shared a post on LinkedIn:
“Pathos AI has secured $365 million in Series D financing, bringing our valuation to ~$1.6 billion.
This marks a major milestone in our mission to transform oncology drug development through artificial intelligence.
With this financing, we’re scaling one of the most ambitious efforts in biotech today: building the largest multimodal foundation model in oncology.
Integrating deep multimodal data to radically improve how we select, develop, and deliver cancer therapies.
Our goal has always been simple and urgent: get the right treatments to the right patients, faster.
This is a bet on a new model for RnD:
– AI that understands biology
– Models that power clinical decision-making
– Trials designed to succeed
– Therapies that get to the right patients, fasterI’m incredibly proud of the Pathos team and grateful to our investors and partners who believe in this mission. We’re just getting started.
To our investors: thank you for believing in this mission.
To our partners, scientists, engineers, and clinicians: thank you for building the future with us.
Let’s go.”
More posts featuring Oncology drug development
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 14:50
Jun 26, 2025, 14:20
Jun 26, 2025, 13:31